We have projects in the South Asian region of Bangladesh. Bangladesh with 160 million people is the 7th largest country by population and is a high growth market. It is one of the Next-11 (N-11) listed countries published by Goldman Sachs. While the country has always been an agriculture major country the economy has been accelerated in recent decades by the apparels (garments) and pharmaceuticals industries. In recent years, on national (government funded) and private levels there has been a growing interest and investment in biotechnology capacity to develop the agriculture, health and biopharma sectors and also to bring these up to global standards. To this end, sponsored by the Bangladeshi government, the genome of jute, the most important cash crop, was sequenced recently by local scientists, and sponsored by a private agribusiness, the genome of the buffalo was sequenced in collaboration with the BGI.
Fig. The biotech facility of Healthcare Pharmaceuticals Ltd (HPL) is in progress (top), and the impression of the expected final construction of a 4 story bio-facility in Phase 1 (below)
ImmunoSYS has focused on the biopharma and agribusiness sectors of Bangladesh. We work with large private companies on individual projects:
- A project with Healthcare Pharmaceuticals Ltd (HPL), a fast growing pharma company that grew out of the Roche team, is working to develop laboratory and animal facilities, core biological teams and processes to enable them the R&D and manufacture of antibodies, immune assays and kits, probiotics, bio-equivalence (BE) analysis, ADME and DMPK, peptides and proteins.
- A project with Phenix Group, one of the largest livestock companies, is working to develop laboratory and animal facilities, processes and to form consortium with academic groups in Bangladesh and the UK to enable them R&D and manufacture of veterinary vaccines, probiotics (for humans and livestock), enzymes and chromium-resistant bacteria.